Clinical Trials · NCT01623206

Desmopressin (DDAVP) in Patients With Colorectal Cancer and Rectal Bleeding

Name: Desmopressin (DDAVP) in Patients With Colorectal Cancer and Rectal Bleeding
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Desmopressin

Phase: Phase 2
Recruitment status: Completed
Sponsor: Laboratorio Elea Phoenix S.A.
Enrollment: 30
Start date: Apr 2013
Locations: 2 sites, Argentina
Primary endpoint: Presence or absence of grade 3 or 4 adverse events related to the study drug, in a maximum of 2 out of 6 patients assessed in each dose level.

View Desmopressin compound reference